PRGO

#2145
PERRIGO COMPANY PLC
11.4801 USD
+2.08%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
11.4600
11.5050
Годовой диапазон
9.2250
22.0100
Дневное изменение
+2.08%
Месячное изменение
+21.42%
6-месячное изменение
-46.65%
Годовое изменение
-46.65%
Предыдущее закрытие
11.2460
Открыть
11.4900
Bid
Ask
Минимум
11.4600
High
11.5050
Объем
117
Открыть полный график

Financials

Обзор Отчетность Статистика Дивиденды
Квартал Год
  • Market Capitalization 1.5802 B
  • Employee 8 100
  • Founded N/A
  • CEO Murray S. Kessler
  • Website www.perrigo.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-1.35
Коэффициент цена/денежный поток
0.45
Дивиденды на акцию
1.16
Дивидендная доходность, %
8.33

Perrigo Company plc

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.

Новости